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Background: Many biologically active compounds bind to plasma transport proteins, and this binding can be
either advantageous or disadvantageous from a drug design perspective. Human serum albumin (HSA) is one of
the most important transport proteins in the cardiovascular system due to its great binding capacity and high
physiological concentration. HSA has a preference for accommodating neutral lipophilic and acidic drug-like ligands,
but is also surprisingly able to bind positively charged peptides. Understanding of how short cationic antimicrobial
peptides interact with human serum albumin is of importance for developing such compounds into the clinics.
Results: The binding of a selection of short synthetic cationic antimicrobial peptides (CAPs) to human albumin with
binding affinities in the μM range is described. Competitive isothermal titration calorimetry (ITC) and NMR WaterLOGSY
experiments mapped the binding site of the CAPs to the well-known drug site II within subdomain IIIA of HSA.
Thermodynamic and structural analysis revealed that the binding is exclusively driven by interactions with the
hydrophobic moieties of the peptides, and is independent of the cationic residues that are vital for antimicrobial
activity. Both of the hydrophobic moieties comprising the peptides were detected to interact with drug site II by NMR
saturation transfer difference (STD) group epitope mapping (GEM) and INPHARMA experiments. Molecular models of
the complexes between the peptides and albumin were constructed using docking experiments, and support the
binding hypothesis and confirm the overall binding affinities of the CAPs.
Conclusions: The biophysical and structural characterizations of albumin-peptide complexes reported here provide
detailed insight into how albumin can bind short cationic peptides. The hydrophobic elements of the peptides studied
here are responsible for the main interaction with HSA. We suggest that albumin binding should be taken into careful
consideration in antimicrobial peptide studies, as the systemic distribution can be significantly affected by HSA
interactions.
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Human serum albumin (HSA) is the most abundant
transport protein present in blood plasma with a normal
physiological concentration of 0.6 mM. It is active as a
monomer with 585 residues and a molecular weight of
66.5 kDa. HSA has a high overall binding capacity due to
a number of diverse binding sites distributed over the
whole protein, and binds numerous endogenous and
exogenous compounds [1]. The two best characterized
binding sites regarding ligand specificity and structural in-
formation are drug site I and drug site II located in sub-
domain IIA and IIIA respectively [2]. HSA is known to
have a preference for accommodating neutral lipophilic
and acidic drug-like ligands, which corresponds well with
its main function as a transporter of fatty acids. Exceptions
to this generalization exist, and basic residues have been
observed as HSA ligands, although only a few experimen-
tal complexes have been published [1]. So far the ex-
perimental basic ligand HSA complexes comprise the
drug site I fluorescence marker dansyl-L-arginine bound
in drug site I, and the anaesthetic compound lidocaine lo-
cated in a novel binding site [3,4].
HSA acts as a negative acute-phase protein, and its
physiological concentration may decrease by as much as a
factor of two in a number of physiological and patho-
logical conditions [5]. This fluctuation in HSA plasma
level affects the equilibrium between the bound and free
fractions of a compound that binds to the transporter pro-
tein, and may affect drug dosage strategies [6]. In cases
where highly hydrophobic compounds bind to HSA, the
overall solubility of the drug in plasma will increase. The
increase of drug solubility in plasma is regarded as benefi-
cial, but a high affinity toward HSA will require higher
dosages and may be a disadvantage [7]. The dual role of
HSA binding depends on compound properties and com-
parative affinity strengths. Drugs binding to HSA are also
prone to alterations caused by allosteric modulations
induced by additional drug and fatty acid binding [7].
Changes in concentration of endogenous and exogenous
ligands in plasma may further induce release of bound
drugs into the free state by competing for the same bin-
ding site and result in toxic plasma levels [7].
Antimicrobial peptides (AMPs) are a part of the innate
immune system of mammals, insects and plants, and act
as a first line of defence against harmful microorganisms
[8-11]. Most AMPs share the common features of an
overall positive charge and an amphiphilic tertiary struc-
ture with clusters of cationic and hydrophobic residues;
however, on the sequence and the secondary structure
level a broad diversity is observed. AMPs are often the
products of a pre-proprotein cleavage that are rapidly
and inexpensively produced as an immune response.
There are several proposed mechanisms for bactericidal
activity of AMPs with interaction and disruption of thebacterial cell membrane being the common trait [12,13].
These unspecific membrane mechanisms are in agree-
ment with experimental observations such as the broad
activity and the need for relatively high AMPs con-
centrations to kill microorganisms. AMPs with receptor-
recognition mechanisms exist, but are distinguished by
having higher activities and specificities than those that
interact with the bacterial membrane [12].
The synthetic cationic antimicrobial peptides (CAPs)
studied in this work have been developed based on trunca-
tion and systematic mutations of lactoferricin, a natural
AMP found in milk [14-16]. The determined pharmaco-
phore established that the minimum motif for antimicro-
bial activity was two cationic charges and two hydrophobic
moieties, and these could be incorporated in sequences as
short as di- and tri-peptides [16]. The structure-activity re-
lationship (SAR) has been further studied by incorporation
of synthetic hydrophobic moieties and variation of the
basic residues [17-20]. Although the peptides are too small
to obtain any specific secondary structure, molecular mod-
elling experiments indicate that flexible amphipathic con-
formations are one of the key properties of CAPs [18]. We
have previously found that CAPs bind to albumin in the
low μM range, and when HSA was included in cell-based
assays at physiological concentrations the minimal inhi-
bitory concentration (MIC) of the CAPs was increased by
an order of magnitude [21]. Albumin binding has also
recently been reported for other AMPs [22]. Previous
ADMET studies on CAPs have mainly focused on protease
stability, however blood plasma stability and stability in
the main metabolic compartments of the body have also
been investigated [20,23-25].
Studies of synthesized lactoferricin as retro, inverso and
retroinverso versions support a bacterial membrane-
dependent mechanism by being unable to differentiate
between any of the activities of the variants [26]. In other
investigations incorporating full D-amino acid variants
and D-amino acids in the CAP sequences, the antimicro-
bial activity is still retained compared with the native
[16,24]. It is highly unlikely that a receptor-recognition
mechanism would be unaffected by any of these structural
modifications. Also supporting the membranolytic hy-
pothesis is the fast bacterial killing and reported MIC
values in the μM range [24]. Molecular dynamic simu-
lations (MD) and NMR liposome dispersion studies of
CAPs in a membrane system provide a reasonable inter-
pretation of possible membrane interaction and indicate
cell lysis by the carpet mechanism [27]. The Kallenbach
group has studied the effect of scaffold attachment and
density enrichment of peptides containing arginine and
tryptophan, and suggest that an increase in density en-
hances antimicrobial activity [28-30].
So far a large amount of work has been done to in-
vestigate the different aspects of CAPs, with the main
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clinical use. As our previous albumin binding study in-
dicates, HSA reduces the fraction of CAP in plasma
when present at physiological concentrations, and
hence reduces the antimicrobial activity. This behav-
iour affects how the CAPs will be managed in the next
step of peptide engineering and if it is feasible to aim
for systemic distribution in plasma. The small and
drug-like molecular structure of the CAPs facilitates in
part the potential for further development into new
drugs. Plasma protein interaction of drug-like mole-
cules is not uncommon as it is the rule rather than the
exception in most cases. Detailed knowledge of the
HSA interaction of CAPs would be useful in develop-
ing these peptides for use in combating the rise of anti-
biotic resistant bacteria.
Herein we report the binding of a selection of
CAPs to human albumin along with competitive bin-
ding experiments with reference ligands for HSA drug
site I and II determined by isothermal titration calori-
metry (ITC) and NMR water ligand observation with
gradient spectroscopy (WaterLOGSY). In order to
examine the interaction in more detail NMR expe-
riments applying saturation transfer difference (STD)
for group epitope mapping (GEM) and INPHARMA
for signal transfer between reference ligand and CAPs
were conducted. Molecular docking was also carried
out to obtain a better understanding of the binding
mechanism.Figure 1 The molecular structure of CAPs and reference ligands usedResults and discussion
We have previously established that several CAPs
surprisingly interact with HSA and bind with low μM
affinity [21]. However the interaction between the pep-
tides and HSA has not been explored in more detail. In
order to examine the binding of CAPs to HSA with re-
spect to drug site I or site II, five peptides were selected
consisting of three active CAPs and two inactive control
peptides as shown in Figure 1. CAP 1 and CAP 5 were
included as controls as they contained either the posi-
tively charged arginines or one of the hydrophobic moi-
eties necessary for activity [16].
Antimicrobial activity
The active peptides CAP 2–4 have been reported else-
where to have MIC values ranging from 1.3 to 83 μM
(Table 1) [21,23,24]. The MIC values of CAP 1 and CAP
5 were above the threshold for all of the bacterial strains
tested, and they are therefore regarded to be inactive as
antimicrobial agents (Table 1). The lack of activity ob-
served for CAP 1 was assumed to be a consequence of its
lack of hydrophobic moieties, thus it does not fulfil the re-
quired pharmacophore. The inactivity observed with CAP
5 can be ascribed to its lack of cationic residues, as it is
being composed only of hydrophobic residues.
Isothermal titration calorimetry
The thermodynamic data for non-competitive ITC ex-
periments are presented in Table 2, and were similar toin this study.
Table 1 Minimal inhibitory concentration values in μM towards selected bacteria
Peptide Ref. S. aureusa MRSAb MRSEc E. colid P. aeruginosae GISAf
CAP 1 >499 >499 - >499 - -
CAP 2 [23] 83 50 25 - - -
CAP 3 [21,23] 7.8, 11 11 3 - - -
CAP 4 [24] 3.2 3.2 1.3 9.7 6.5 3.2
CAP 5 >523 >523 - >523 - -
aStaphylococcus aureus strain ATCC 25923.
bMethicillin resistant Staphylococcus aureus ATCC 33591.
cMethicillin resistant Staphylococcus epidermidis ATCC 27626.
dEscherichia coli ATCC 25922.
ePseudomonas aeruginosa ATCC 27853.
fGlycopeptides intermediate-resistant Staphylococcus aureus CCUG 43315.
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tide CAP 1 did not bind to HSA, whereas the active
peptides CAP 2–4 and the control peptide CAP 5 were
found to interact with similar Kd values in the low μM
range. Raw data along with integrated heats and the
binding isotherm model of a typical non-competitive
titration experiment is presented in Figure 2 for CAP 4.
The binding constants Kd for CAP 2–5 were in the
same μM range 22–25 μM (99–100 μM) (data obtained
with MicroCal iTC200 are shown in parenthesis), indica-
ting that all of the CAPs bind with the same affinity to-
wards HSA (Table 2). The binding profiles show that
there was both a favourable negative enthalpic and a posi-
tive entropic contribution to the free energy. For the
known site I reference ligand Wrf (warfarin) the binding
strength and thermodynamic profile were found to beTable 2 Thermodynamic ITC data for CAPs and reference liga
Ligand Kd
c,† nd, ‡
CAP 1 - -
CAP 2a 23 ± 8 0.67 ± 0.07 −
CAP 3a 22 ± 9 (99 ± 6)b 0.77 ± 0.07 (0.36 ± 0.03)b −6.36 ± 0
CAP 4a 25 ± 9 0.57 ± 0.08 −
CAP 5b (100 ± 13) (1.01 ± 0.05) (−
Wrfb (site I) 9 ± 4 (28 ± 4) 1.15 ± 0.04 (1.02 ± 0.02) −6.87 ±
Dglyb (site II) 11 ± 4 (40 ± 2) 1.08 ± 0.05 (1.16 ± 0.01) −6.78 ±
CSC 5300 Nano-Isothermal Titration Calorimeter III data, values obtained by MicroC
n denotes the stoichiometric ratio).
aThree parallels.
bTwo parallels.
cError limits taken as the average of the maximal difference between Kd and calculated
Titration Calorimeter III, default error calculations based on least square fit and χ2 with
dError limits are the averages of ± 95% confidence interval of the parallels CSC 5300
least square fit and χ2 with iTC200.
eError limits taken as the average of the maximal difference between ΔG and calculate
Titration Calorimeter III, default error calculations based on least square fit and χ2 with
f Error limits are the averages of ± 95% confidence interval of the parallels CSC 5300
least square fit and χ2 with iTC200.
gError limits by cumulative addition of error limits of ΔG and ΔH.
†Deviation between parallels < 16%, except Wrf with 39%. ‡ Deviation between para
< 12%. $Deviation between parallels < 20%, except CAP 4 with 63%. The symbol “-“dsimilar compared with previous published studies, with
our Kd 9 μM (28 μM) slightly higher compared with the
previously reported values 2.9–3.8 μM [31-33]. The bin-
ding affinity for drug site II reference ligand Dgly (dansyl-
glycine) of 11 μM (40 μM) is also slightly higher than the
reported 1.7–3.2 published in other studies [34,35]. The
corresponding free energies for Wrf and Dgly were re-
spectively −6.9 (−6.2) and −6.8 (−6.0) kcal/mol, with both
favourable enthalpic and entropic contributions. By com-
parison, the CAPs binds with Kd in the range 22–25 μM
(99–100 μM), corresponding to free energies of −6.3
to −6.4 kcal/mol (−5.5 kcal/mol). When comparing the
data obtained with the two instruments, the MicroCal
iTC200 and the CSC 5300 Nano-Isothermal Titration
Calorimeter III, the data values were observed to contain
a variation. But there were consistency within thends Wrf and Dgly
ΔGe,§ ΔHf, # TΔSg, $
- - -
6.32 ± 0.18 −3.7 ± 0.5 2.6 ± 0.7
.19 (−5.46 ± 0.04)b −2.8 ± 0.4 (−16.7 ± 1.3)b 3.5 ± 0.6 (−11.2 ± 1.4)b
6.28 ± 0.19 −5.2 ± 1.0 1.1 ± 1.1
5.46 ± 0.07) (−3.0 ± 0.2) (2.5 ± 0.3)
0.19 (−6.21 ± 0.07) −2.4 ± 0.1 (−3.3 ± 0.1) 4.4 ± 0.3 (2. ± 0.)
0.20 (−6.00 ± 0.02) −4.5 ± 0.3 (−5.5 ± 0.1) 2.3 ± 0.5 (0.5 ± 0.1)
al iTC200 presented in parenthesis. (Kd in μM, ΔG, ΔH and TΔS in kcal/mol,
Kd ± error limits 95% confidence interval from Ka CSC 5300 Nano-Isothermal
iTC200.
Nano-Isothermal Titration Calorimeter III, default error calculations based on
d of ΔG± error limits 95% confidence interval from Ka CSC 5300 Nano-Isothermal
iTC200.
Nano-Isothermal Titration Calorimeter III, default error calculations based on
llels < 21%. § Deviation between parallels < 3%. # Deviation between parallels
enotes no measured binding.
































Figure 2 ITC binding data of CAP 4 titrated into HSA. (A) Raw
data as μcal/sec is plotted against time in min with the control
buffer experiments shown in bold line. In (B) the fitted independent
model is shown as dotted line to isotherm data point presented as
open circles. The first data point is omitted from the analysis. The
data was obtained with the CSC 5300 Nano-Isothermal Titration
Calorimeter III. Figures made in GrapPad Prism v5.00.
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mined with both instruments, hence if comparing the Kd
obtained with the MicroCal iTC200 data the values showed
3–4 times lower affinities compared with the CSC 5300
Nano-Isothermal Titration Calorimeter III, e.g. 99 μM
compared with 22 μM for CAP 3, 28 μM and 9 μM for
Wrf and 40 μM and 11 μM for Dgly. Hence comparing
the CAP 3 and CAP 5 binding in Table 2, CAP 5 was
considered to bind in the same affinity range as the rest of
the CAPs. The major difference in the comparison of the
data between the instruments was the enthalpy-entropy
profile of CAP 3 that changed to high favourable enthalpy
but unfavourable entropy contribution with the MicroCal
iTC200. The stoichiometry of the reference ligands Wrf
and Dgly and the control peptide CAP 5 revealed a 1:1
ratio. Whereas the other peptides, CAP 2–4, the stoi-
chiometry decreased to 0.6-0.8 for the CSC 5300 Nano-
Isothermal Titration Calorimeter III instrument data, andeven lower (0.4) for CAP 3 in the MicroCal iTC200
obtained data. The control buffer experiments did not
show any significant heat of dilution signal for any of the
experiments.
Competitive binding in drug site II
To further try to identify which of the numerous binding
sites of HSA the CAPs were interacting with, competitive
ITC experiments with the reference ligands Wrf and Dgly
were conducted. Wrf only interacts with drug site I,
whereas Dgly has a secondary binding site in drug site I in
addition to its primary site in drug site II (Additional file 1:
Figure S1). The competitive ITC results showed that the
peptides competed with the drug site II reference ligand
Dgly, and not with drug site I ligand Wrf. Competition
was indicated by a significant decrease in the heat signals
in all experiments where CAP 2, CAP 3, and CAP 4 were
titrated into HSA incubated in 1:1 molar ratio with either
Wrf or Dgly (data not shown). More pronounced was the
decrease seen in the signals when HSA was incubated with
1:3 molar ratio either with Dgly or control peptide CAP 5,
as shown in Figure 3 for CAP 3 titrations. The competitive
effects for CAP 3 were equally strong for Dgly and CAP
5. Similar results were obtained for CAP 5 titrations into
HSA incubated with Wrf or Dgly in molar ratio 1:3, data
provided in Additional file 1: Figure S2. Control experi-
ments reversing the titration order of the reference ligands
and CAPs were performed for selected peptides and
showed the same trends in competition pattern, data pro-
vided in Additional file 1: Figures S3 and S4. None of the
control experiments with buffer in the cell indicated any
significant ligand-ligand interactions in the competitive
experiments. It should be noted that the competition ex-
periments between Wrf and the peptides might indicate
partial displacement of the ligand incubated with HSA.
However, a more likely explanation is the alteration of the
free ligand concentration due to peptide-Wrf interactions
in solution. We see some interaction between Wrf and
peptides in the NMR experiments (see below), which pos-
sibly lower the free concentration of the peptide in the
ITC competition experiments. Nonetheless, the ITC data
is clear on the main binding site as is evident from the
Dgly competition experiments.
As a complementary technique, NMR was used to
probe binding to HSA with WaterLOGSY experiments
[36]. Weak binding could be confirmed for CAP 3 and
CAP 5, but not for CAP 1 (Additional file 2: Figures S5
and S6). The CAP 3 peptide was selected as a repre-
sentative CAP for competitive binding experiments in
WaterLOGSY experiments versus Wrf and Dgly. The
WaterLOGSY response to addition of competitive ligand
shows a clear reduction in CAP 3 WaterLOGSY when ti-
trated with Dgly but not with Wrf (Figure 4), thus con-
firming the ITC finding that CAP 3 and Dgly bind to the
A B
C D
Figure 3 ITC raw data and integrated heats of CAP 3 titration into HSA. (A) CAP 3 titrated into HSA solution (reference data) and
(B) competitive experiments of HSA incubated 1:3 molar ratio with drug site I reference ligand Wrf, (C) with drug site II reference ligand
Dgly and (D) with control peptide CAP 5. Control buffer titration is shown in red line in the upper panel and open squares in the lower
panel. (The molar ratio in the buffer control was set to the same as the protein ligand ratio merely for the purpose of interpretation). Data
collected with MicroCal iTC200. Figures made in Origin® 7.0.
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interactions between Dgly and the studied CAPs before
the addition of HSA to the sample. However, a weak direct
interaction between CAP 3 and Wrf in solution was ob-
served as weak direct NOE correlations (also inverting the
NOE sign to negative) between the two ligands in
trNOE experiments as well as a reduction in relaxationtimes for the biphenyl resonances of CAP 3 upon Wrf
addition (data not shown).
The CAPs interact with drug site II with their hydrophobic
moieties
The INPHARMA results of CAP 3 and Dgly show signal
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Figure 4 Competetive WaterLOGSY between CAP 3 and Dgly (A) and Wrf (B). (A) shows how Dgly perturbs 1:1 linear buildup of the
WaterLOGSY effect which is proportional to protein binding, in CAP 3 relative to the concentration of added Dgly, whereas (B) shows that Wrf
does not produce the same effect. Ligand:protein ratio was 20:1.
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(see Figure 5 and Table 3). This is best seen in the signal
transferred from the tertiary amine methyl groups of
Dgly and the hydrophobic moieties of CAP 3. The epi-
tope mapping of Dgly is in agreement with the results
reported in Lucas et al. showing that the strongest inter-
action is between the N-methyl groups as well as the
glycine methylene group of Dgly and HSA [37]. It was
clear from the data that the cationic arginines did not
contribute to the interaction between CAP 3 and drug
site II of albumin as no signal was transferred to these
parts of the peptide.
The saturation transfer difference with group epitope
mapping further confirmed the INPHARMA results.
The arginines of CAP 3 were not excited by saturation
of protein methyl groups, whereas the hydrophobic parts
of the molecules clearly lit up as seen in Figure 6, indi-
cating that they directly take part in interactions with
the protein. For Dgly the whole molecule is excited
which is in agreement with the INPHARMA results.
Exploration of modelled binding modes
Drug site II is located in subdomain IIIA of HSA, and
has similarities to drug site I in subdomain IIA. Both of
the sites are characterized by an apolar pocket and a
basic polar patch at the binding site entrance, with a
preference for aromatic drug-like ligands with a peri-
pherally negative charge [38,39]. The main difference
between the two sites is the packing environment, which
enables drug site I to be larger with an enhanced flexi-
bility compared to drug site II [38]. The two fatty acid
binding sites (FA) 3 and 4 are also associated with drug
site II. In FA3 the methylene tail of the fatty acid is bent
into the apolar pocket of drug site II, and in the case of
FA4 the carboxyl group of the fatty acid is hydrogen
bonded with residues in the polar patch at the site
entrance [40,41]. As the HSA ligand preferences for this
site are aromatic and negatively charged small ligands,the experimentally determined binding of cationic pep-
tides interacting with this site by both ITC and NMR
was unanticipated. The comparably larger size and the
multiple positive charges provided by two arginines and
the protonated N-terminal of the peptides were expected
to exclude CAPs as drug site II ligands.
To further investigate the binding mechanism molecu-
lar docking was performed targeting drug site II of HSA.
In general, the modelled docking poses and scores sup-
ported the experimental findings from both the ITC and
NMR data. In all of the docking experiments, the refe-
rence drug site II ligand Dgly was docked in a position
similar to that occupied by the ligand from original
structure, and was located at the top of the docking
score ranking list. The modelled conformations of Dgly
were found to be virtually identical for all of the target
structures, which were accommodated in the apolar
pocket of site II. The docking mode was in agreement
with the NMR INPHARMA and STD GEM interpret-
ation of Dgly binding. The tertiary amine was buried in
the inner hydrophobic part of the site, with the carboxy
and sulphate group hydrogen bonding with the polar
patch residues at the site entrance. Only docking poses
of the CAP library that would compromise the volume
occupied by Dgly were accepted, as the results from the
competitive ITC data and the NMR WaterLOGSY
indicate. The reference ligand Wrf for drug site I and
the non-binding peptide CAP 1 were added as negative
controls, and were generally given docking scores in the
lower part of the ranking list.
The main difference between the docking targets was
the conformation of the entrance residue Arg410. This
residue is flexible and known to be a highly ligand indu-
cible residue, which is also reflected by high B factors in
the structure of 1E78 and 2BXF, or disordered as found
for crystal structures 2XW1 and 2XVQ. Three different
main conformations were observed, either pointing to-






















































Figure 5 Protein mediated ligand-ligand contacts. (A) trNOESY spectra of CAP 3 versus Dgly acquired using 100 ms mixing time for
INPHARMA analysis. Green rectangles indicate groups that transfers signal to each other mediated by the protein. (B) Labeling of CAP 3 and the
drug site II reference ligand Dgly in the INPHARMA experiments. The same notation was also used in Table 3.
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mediate position was observed for the apo structure
1E78. With Arg410 in 2XVQ resembling the 2XW0
conformation and the side chain in 2XW1 in a similar
position as seen in 2BXF. The apo structure 1E78 did
not produce satisfactory poses for the system with a fewexceptions, and comparing the docking score with the
experimental binding data indicated a too weak inter-
action for these poses. Hence, when the side chain was
positioned in the middle of the entrance of drug site II,
Arg410 was blocking the binding site. Docking with
2XW0 and 2XVQ as target structures did not produce
Table 3 NMR-INPHARMA results of CAP 3 versus Dgly
Entry Dgly
Label 1 2 3 6 7 8 12/13 15
CAP 3
19 + - - n/a - - +++ ++
21 + n/a + n/a n/a ++ +++ ++
22 ++ n/a ++ n/a n/a ++ +++ ++
25 ++ n/a ++ n/a n/a n/a +++ ++
26 ++ n/a ++ n/a n/a - +++ +
27 n/a n/a n/a n/a n/a n/a +++ n/a
36 + + - + + - +++ +
38 - - - ++ ++ ++ +++ +
39 + n/a + n/a n/a ++ +++ ++
40 + n/a + n/a n/a ++ +++ +
+, ++, and +++ denotes transferred signals and strength between groups in
the two ligands (see Figure 5 for labeling), - indicate no signal transferred
between groups and n/a denotes not available signals.
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CAP 4 were obtained. The Arg410 is pointing toward
Glu492 in a similar conformation for these structures,
which does not seem to be the optimal conformation for
CAP binding.
For 2BXF and 2XW1, which had Arg410 conforma-
tions toward Gln390, all of the peptides and the refe-
rence ligands were satisfactorily docked and with scores
in agreement with the experimental ITC data in Table 2.
However, 2XW1 produced more numerous and con-
sistent of accepted poses compared to 2BXF for all of
the binding CAPs. 2XW1 was also able to rank the non-
bonding control peptide CAP 1 at the bottom of the
ranking list. As a consensus for the accepted poses for
these targets, the peptides interact with drug site II by
one of the hydrophobic moieties, either the indole for
CAP 2 or the Bip side chain for CAP 3 and CAP 5 re-
spectively. Interestingly, only the benzyl capping group
residue was found to interact with drug site II for CAP
4. This is most likely due to the large size of the syn-
thetic Tbt side chain in this peptide. Compared with the
NMR INPHARMA results and the epitope mapping by
others [37] the signal transferred between the different
structural parts of Dgly and CAP 3 was in agreement
with how deep they would be located in the binding site.
For instance the signal from the glycine methylene
group show indications of transferring to parts of the
CAP 3 which would occupy the outer part of drug site
II.
Figure 7 shows docking poses for the highest accepted
ranked pose of CAP 3 and CAP 4 superimposed on the
docked Dgly molecule for target structure 2XW1. The
docking scores for the 2XW1 target were in the range
of −6.6 to −8.3 kcal/mol for the top ranked accepted pose
of the CAPs and −9.0 kcal/mol for Dgly, corresponding to
lower μM binding constants. Whereas for the rangefor 2BXF was −5.7 to −7.7 kcal/mol for the CAPs
and −8.0 kcal/mol for the top ranked pose of Dgly. The
CAP 3 was top ranked for both targets with a score
of −10.8 (2XW1) and −9.0 (2BXF) kcal/mol which corres-
pond to a binding constant in lower nM region. In these
two poses the Bip binds deeper in the binding site than
any of the other poses for this peptide, and it is uncertain
if it corresponds to a real binding mode when comparing
with the experimental binding constant. In general the
control peptide CAP 5 displayed docking poses that re-
sembled the Bip conformation of CAP 3. Control peptide
CAP 1 was given docking scores that correspond to mid
μM Kd values, and docked poses were exclusively located
outside drug site II for the targets 2BXF and 2XW1.
From the docking poses, the interaction with drug site
II of HSA depends only on the hydrophobic elements of
the peptides, and does not involve the cationic residues
that are vital for antimicrobial activity. The models are
in good agreement with the experimental NMR results
in this aspect. This is also evident when comparing the
experimental and modelled interaction of the two con-
trol peptides CAP 1 and CAP 5 with HSA. The control
for the cationic part of the pharmacophore, CAP 1, does
not bind to HSA. Whereas CAP 5 which is containing
only hydrophobic residues interacts with drug site II
with similar affinity as the antimicrobial CAPs. The argi-
nines were observed to interact with nearby negatively
charged surface residues in the docking poses, but no
consistent patterns were observed. The solvent states of
the arginine residues are considered equal in the bound
and free form of the peptides, and will therefore not
contribute to the free energy of the binding. It seems
that the CAPs have evaded their own undesirable cha-
racteristics as drug site II ligands, as they only interact
with one of their lipohilic groups.
Avoiding albumin binding for CAPs would be chal-
lenging, as the hydrophobic moieties are crucial for their
antimicrobial activity. But observations in the docking
poses of CAP 4 might be a starting point in changing
the albumin binding properties. The bulky Tbt side
chain of this CAP was observed to be too large to inter-
act satisfactory with drug site II, and hence the inter-
action was achieved by binding with the C-terminal
capping benzyl. If a lipophilic group with similar proper-
ties would replace the benzyl, lower albumin binding is
anticipated.
Crystallization
The attempts to crystallize and obtain a complex structure
of HSA and CAPs resulted in an apo-structure with fatty
acid molecules bound in the seven fatty acid binding sites
(Additional file 3), as previously described in the literature
[40-42]. In our apo-fatty acid structure we found that for
the first time to our knowledge, the direction of the fatty
Figure 6 Protein contact mapping of ligands. (A) STD spectra of CAP 3, Dgly and HSA in 100:1 ratio (red) superimposed on a dpfgse proton
spectra acquired with a 10 ms T2 filter for protein suppression (grey). In (B) the exited hydrophobic parts of CAP 3 are indicated in green, and in
(C) the entire molecule of drug site II reference ligand Dgly was exited.
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group was found to form strong ionic interactions (<3 Å)
with the guanidinium group of Arg218, see Additional file 3
Figure S8. Data collection and model refinement statistics
are presented in Additional file 3: Table S1.Conclusions
In this study we have reported how CAPs interact with
HSA within μM affinity by ITC in agreement with previ-
ous studies by our group [21]. We have identified the







Figure 7 Molecular models of ligand binding to human albumin obtained with docking. (A) Docking poses of CAP 3 in yellow (docking
score −8.1 kcal/mol) superimposed on Dgly in magenta (docking score −9.0 kcal/mol) with target 2XW1. (B) Docking poses of CAP 4 in orange
(docking score −6.6 kcal/mol) superimposed on Dgly in magenta (docking score −9.0 kcal/mol) with target 2XW1. The calculated electrostatic
potential surface of 2XW1 is shown. CAP 3 is interacting with drug site II with the biphenyl, whereas CAP 4 is binding with the C-terminal
capping benzyl. The lipophilic group in each peptide is comprising the volume occupied by the docked Dgly conformation. Arg410 is omitted in
the figures merely for the purpose of clarification, as it would partly cover the bound Dgly and CAPs.
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hydrophobic moieties present in the peptides. Both
NMR experiments and molecular modelling results sup-
port that the cationic arginine residues of the peptides
do not contribute to the interaction. Since the hydro-
phobic moieties are an important part of the pharmaco-
phore of CAPs, it will be challenging to design peptides
with satisfactory activity with reduced albumin binding
properties, and hence it is anticipated that HSA binding
of CAPs will be an issue that needs to be addressed in
future drug administration strategies.
Methods
Ligand library
The molecular structures of the ligands used in this
study are presented in Figure 1. The synthesis of CAP 2
[23], CAP 3 [21,23] and CAP 4 [24] have been pub-
lished elsewhere by our group. The control peptides
CAP 1 and CAP 5 were purchased from PolyPeptide
Laboratories (Strasbourg, France). Reference ligands for
drug site I warfarin (A4571) and for drug site II dansyl-
glycine (D0875) were purchased from Sigma. CAP 2–4
have a common RXR-Bzl scaffold, with X containing a
varying hydrophobic side chain. The side groups were
indole (Trp) for CAP 2, biphenyl (Bip) for CAP 3 and
tri-tert-butyl substituted indole (Tbt) for CAP 4. CAP 1
and CAP 5 were included as inactive controls represent-
ing the cationic charge or the hydrophilic moiety of the
active peptides respectively. Control peptide CAP 1 con-
tained a methyl group (Ala) as side chain in X that was
flanked by arginines and had an amide capped C-terminal. The control peptide CAP 5 had a Bip in the
side group for X flanked by alanines and also contained
an amide capped C-terminal. The peptides were chosen
for this study based on the diversity in lipophilicity and
size of the varying hydrophobic side chain in residue X.Microbiological studies
The antibacterial activity of CAP 1 and CAP 5 were
tested towards Staphylococcus aureus strain ATCC 25923,
methicillin resistant Staphylococcus aureus strain ATCC
33591 and Escherichia coli strain ATCC 25922. The stu-
dies were performed by Toslab AS employing standard
methods [43].Isothermal titration calorimetry studies
The experiments were either performed on a CSC 5300
Nano-Isothermal Titration Calorimeter III (Calorimetry
Sciences Corporation, Utah, USA) with a cell volume of
1 mL, or a MicroCal™ iTC200 with a cell volume of
200 μL (MicroCal, LLC., Northampton, MA, USA). In
all experiments lyophilized HSA ~99% essential fatty
acid and globulin free (Sigma A3782), was weighed out
to a nominal concentration and dissolved prior to the
experiments in buffer 50 mM Tris, 10 mM CaCl2,
pH 7.4 at 25°C. All ligands and peptides were dissolved
in the same buffer. Control titrations of ligand into buf-
fer were performed in duplicate to investigate if the heat
of dilution would generate a significant signal, and if
ligand-ligand interactions were present in the com-
petitive experiments. The same settings as for the
Sivertsen et al. BMC Structural Biology 2014, 14:4 Page 12 of 14
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the control experiments.
In all experiments applying the CSC 5300 Nano-
Isothermal Titration Calorimeter III, the HSA concen-
tration was 0.1 mM and all other peptides and ligand
concentrations used were 2.1 mM. In the non-competi-
tive design 33 consecutive 3 μL injections were carried
out with 200 s spacing between each injection. A stirring
rate of 150 rpm and an isotherm temperature of 25°C
were applied. The response signal was measured at 1 s in-
tervals, and a 200 s baseline was collected prior to the first
injection for the purpose of assessing the baseline. Non-
competitive experiments were carried out either in dupli-
cates or triplicates. In the competitive experimental design
HSA was pre-incubated with either the drug site I war-
farin or site II dansylglycin ligands, or the peptides CAP
2–4 in a 1:1 molar ratio. In total 40 consecutive injections
were performed with a volume of 5 μL and a spacing of
300 s. The first injection in the series had a dummy vol-
ume of 3 μL to account for leakage from the syringe and
was omitted in the final analysis. Prior to the first injec-
tion, a baseline of 100 s was recorded to ensure instru-
ment stability. The solution was stirred at 150 rpm, and
the isothermal temperature set to 25°C. All competitive
experiments were carried out in duplicate. For the experi-
ments conducted on the MicroCal™ iTC200 instrument the
HSA concentration used was 0.21 mM, and the concen-
tration of ligands and peptides were 4.3 mM. In total, 29
injections of 1.35 μL with 180 s spacing between each in-
jection were titrated. The first injection was set to a
dummy volume of 0.1 μL due to syringe leakage in the
baseline equilibration step. An initial delay of 180 s was
set to sample the baseline. The applied reference power
was 6 μcal/s and an isothermal temperature of 25°C was
used. The solution was stirred at 1000 rpm, applying
high feedback mode and a filter period of 5 s. For com-
petitive experiments HSA was pre-incubated with the
reference ligand or peptide at a molar ratio of 1:3. For
the selected peptides CAP 3 and CAP 5 competitive ex-
periments with reversed order of the reference ligands
and the CAP were performed as a control of titration
order. The same ITC settings were applied for the non-
competitive and competitive experiments with the
MicroCal™ iTC200.
The ITC data was analyzed using the NanoAnalyse
software from TA Instruments, v2.0.1 (Waters LLC, New
Castle, DE, US) or Origin® 7.0. Independent model fit
was used to generate the binding isotherm, and the
first injection in all titration experiments was omitted
in the binding isotherm analysis. The heat of dilution
and unspecific binding signal corresponding to the
last injection in each experiment was subtracted from
all of the heat signals. The quality of the model fit
was examined using the statistical modules of thesoftware, the 95% confidence interval based on a
1000 trial calculations in the NanoAnalyze package,
and the default non-weighted least square calculation
in Origin® 7.0.
NMR
All NMR experiments were acquired on an Agilent (Varian)
inova spectrometer operating at 599.934 MHz for 1H,
equipped with a 2nd generation inverse triple resonance
HCN cold probe. NMR samples were prepared in 50 mM
Tris buffer, 10 mM CaCl2, pH 7.4 at 25°C, to final concen-
trations of 40 μM HSA and 800 μM ligand (Wrf, Dgly,
CAP 1, CAP 3 and CAP 5). 1D-NOE ePHOGSY for
ligand detection via WaterLOGSY [36,44] was acquired as
256 transients, 8 k complex points and 12000 Hz sweep
width using 1500 ms mixing time, 1.0 s relaxation delay
and a solvent selective pulse of 2.4 ms width at 12 dB.
Each ligand addition was recorded with standard 1H spec-
tra using watergate (3919) solvent suppression and blank
controls were acquired before the addition of HSA sam-
ples for STD spectra [45] and transferred NOE (trNOE)
spectra for INPHARMA-type analysis [46] were prepared
in deuterated buffer to final concentrations of 10 μM HSA
and 1 mM ligand (1:100). STD spectra were acquired in
256 transients, 6 k complex data points and 12000 Hz
sweep width. Saturation was achieved by 50 cycles of
45.8 ms gaussian shaped saturation pulses centered at
0.4 ppm for the “on” resonance and at 15 ppm for the
“off” resonance fid. The difference spectra were produced
by internal subtraction and all spectra were acquired with
both sculpted solvent suppression during the PFG spin
echo and 500 ms solvent presaturation during the relax-
ation delay. The protein signals were suppressed by a
10 ms T1ρ-spinlock. Finally, the spectra were multiplied
with a 3 Hz exponential window function. For reference,
double PFG spin echo 1D proton spectra were acquired
using the same parameters, including the 10 ms T1ρ-
spinlock for protein suppression. NOESY spectra for
INPHARMA were acquired in 8 transients as 1440 × 256
data points at mixing times of 50, 100, 200 and 500 ms
using zero quantum (ZQ) filter and grad-90-grad
randomization. All samples were monitored for line broa-
dening, quickened relaxation and NOE inversion to spot
any direct interaction between ligands before the addition
of HSA.
Crystallization studies
An attempt was made to obtain crystals of the human
albumin CAP complex for structural determination.
Crystallization trials were carried out with recombinant
human albumin (rHA) using both the soaking method
with fatty acid rHA complex and co-crystallization
methods as described by the Curry group [38,40]. Only
the soaked fatty acid rHA complex produced crystals of
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for the crystallization of rHA in complex with fatty acid
are provided in the Additional file 3.
Molecular docking
Targets used in the molecular docking experiments were
the apo HSA crystal structure 1E78 [47], and the four
complex structures 2BXF [38], 2XW1 [3], 2XVQ [3], and
2XW0 [3]. The peptide library was built and prepared in
LigPrep, version 2.5 [48], with their stereochemistries
retained as all L-residues. All receptor targets were proc-
essed using the Protein Preparation Wizard in Maestro,
version 9.3 [48]. The docking grids set up in Glide, version
5.8 [48], were centred either on the ligand in the complex
structure, or one of the residues belonging to drug site II
for the apo structure. A maximum size of ligand diameter
and a 14 Å mid point box were utilized. For the docking
experiments the standard precision (SP) mode was ap-
plied. The grid generation and docking procedure was re-
peated due to the size difference of the smaller reference
ligands and the larger CAPs, applying CAP 3 as reference
ligand for the box size. The ligand library was comprised
of the CAPs and the reference ligands Wrf and Dgly pre-
sented in Figure 1. For the targets 2XW1 and 2XVQ the
side chain coordinates of Arg410 were not reported, and
the residue was therefore built and minimized by Prime,
version 3.1 [48].
Additional files
Additional file 1: Competitive ITC binding data. Figure S1. shows
competitive ITC binding data for Wrf and Dgly. Figure S2. shows
competitive ITC binding data for CAP5 with drug site I ligand Wrf and
drug site II ligand Dgly. Figure S3. presents the competitive experiments
for Wrf with HSA incubated with either CAP3 or CAP5. Figure S4. shows
competitive experiments for Dgly with HSA incubated with either CAP3
or CAP5.
Additional file 2: WaterLOGSY experiments. Figure S5. presents
WaterLOGSY of HSA and Wrf, Dgly and CAP 1, while Figure S6. shows
WaterLOGSY of HSA and CAP1, CAP3 and CAP5.
Additional file 3: Crystal structure of albumin-palmitic acid complex.
Crystallization conditions and details of data collection as refinement
procedures are presented. A brief discussion of the crystal structure is
provided along with data collection and refinement statitistics (Table S1).
Figure S7. shows the mount crystal, and Figure S8. presents the electron
density for the fatty acid binding mode of PA 7 in FA site 7.
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